BeiGene (BGNE) Earning Somewhat Favorable News Coverage, Analysis Finds
Headlines about BeiGene (NASDAQ:BGNE) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BeiGene earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.3996135461239 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- [$$] Celgene Invests in Acceleron, BeiGene (finance.yahoo.com)
- BeiGene : Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO (4-traders.com)
- BeiGene, Ltd. (BGNE) registers a price change of 14.32% while Syros Pharmaceuticals, Inc. (SYRS) finishes with a … – Stocks Gallery (stocksgallery.com)
- Celgene Invests in Acceleron, BeiGene – Barron’s (barrons.com)
- BeiGene, Ltd. (BGNE) PT Raised to $120 at Maxim Group – StreetInsider.com (streetinsider.com)
Shares of BeiGene (NASDAQ:BGNE) opened at 110.58 on Thursday. The firm’s market capitalization is $4.40 billion. BeiGene has a 12-month low of $26.43 and a 12-month high of $111.99. The company has a 50-day moving average of $88.28 and a 200 day moving average of $88.28.
Several analysts recently issued reports on BGNE shares. Maxim Group reaffirmed a “buy” rating and issued a $77.00 price target on shares of BeiGene in a report on Monday, September 11th. Zacks Investment Research raised shares of BeiGene from a “sell” rating to a “buy” rating and set a $79.00 price target on the stock in a report on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $86.00 price target (up from $43.00) on shares of BeiGene in a report on Tuesday, August 15th. Morgan Stanley reaffirmed an “overweight” rating and issued a $83.00 price target on shares of BeiGene in a report on Monday, July 10th. Finally, Robert W. Baird upped their price target on shares of BeiGene from $44.00 to $58.00 and gave the company an “outperform” rating in a report on Thursday, July 6th. Eight analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $90.50.
TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/05/beigene-bgne-earning-somewhat-favorable-news-coverage-analysis-finds.html.
In other BeiGene news, Director Donald W. Glazer sold 10,810 shares of BeiGene stock in a transaction on Monday, July 10th. The stock was sold at an average price of $72.15, for a total transaction of $779,941.50. Following the completion of the transaction, the director now directly owns 7,206 shares of the company’s stock, valued at $519,912.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 176,056 shares of the business’s stock in a transaction on Friday, August 11th. The shares were bought at an average cost of $71.00 per share, with a total value of $12,499,976.00. The disclosure for this purchase can be found here. 19.90% of the stock is owned by company insiders.
BeiGene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.